The fast-paced progress in the field of genomics over the past quarter-century has brought about significant advances in generating the amount of genomic data available with considerably reduced the cost of genome sequencing/genotyping and thus it will improve analysis and disease management abilities.
The basic costs related to various techniques and methodologies for sequencing genomes is of significance as they impact the scope and scale of all genomics research projects. These projects will then translate into genomics-based disease management and diagnosis.
With the expanding scale of human genetics studies and the growing number of clinical applications for genome sequencing, cost of genome sequencing is an important consideration.
“Since improvement in genome-sequencing methodologies and innovations will keep on advancing, one can promptly expect a continuous lowering in the cost of human genome sequencing. The key factors to consider while assessing the ‘value’ related with an estimated cost for producing a human genome sequence – specifically, the amount of the genome (whole versus exome), quality, and related data analysis (assuming any) – will be relied upon to remain as before. With software and flowcell progresses on existing populace scale DNA-sequencing platforms anticipated in the coming years, the nature of the produced sequence data and the related costs will probably keep on being dynamic. Accordingly, proceeded with consideration should be paid to the paid by which the expenses related with genome sequencing are calculated not simply from a sequencing point of view but rather more comprehensively from collection to understanding,” said Praveen Gupta, managing executive, Premas Life Sciences, a specialized life science distribution organization.
Premas as a team with IncellDx, Inc, has as recently introduced new cervical disease screening tool “IncellDx HPV Oncotect 3Dx in India. The time isn’t too far away when most patients entering the healthcare system will have their genome sequenced before clinical evaluation.
“Consequently, the composition of genetic testing will be vitally changed to focus on the analysis of genomic data with regards to an individual, their immediate and long-term needs, their personal decisions and their environment. This won’t be an overnight revolution, as it will be some time before developing bioinformatics answers for interpreting genomic data can straddle both high quality and low effort. Once such solutions increase more extensive traction, high-quality healthcare will turn out to be more available to a more extensive population,” additionally included Praveen Gupta.
The genetic testing assumes a vital part in enhancing treatment result in non-transmittable diseases (NCDs, such as cancer, heart disorders, and diabetes. It also allows early and precise diagnosis of disease risk and occurrence and guides prevention and personalized medical intervention. Around percent of deaths in India are attributed to non- communicable diseases, including heart disorders, cancer, and diabetes, as per information released by World Health Organization in 2017.
Almost 23 percent are at risk of premature death because of such diseases. In India, a total of 58,17,000 deaths were assessed from diseases like cancer, diabetes and heart problems in 2016, WHO data included.